BrahMos WORLD INDIA MADHYA PRADESH BHOPAL SPORTS BUSINESS FUN FACTS ENTERTAINMENT LIFESTYLE TRAVEL ART & LITERATURE SCIENCE & TECHNOLOGY HEALTH EDUCATION DIASPORA WTN SPECIAL OPINION & INTERVIEW GOSSIP CORNER RECIPES DRINKS BIG MEMSAAB 2017 BUDGET 2017 FUNNY VIDEOS VIRAL ON WEB PICTURE STORIES Mahakal Ke Darshan
ABOUT US PRIVACY POLICY SITEMAP CONTACT US
logo

Breaking News

Breakthrough in chikungunya may come from IIT-Roorkee

Thursday - October 5, 2017 8:34 pm , Category : SCIENCE & TECHNOLOGY

Roorkee Oct 5 (IANS) In a move that could lead to a breakthrough in combating chikungunya the Indian Institute of Technology (IIT)-Roorkee has claimed to have discovered the anti-viral potential of a drug piperazine -- used for worm infections.



Medicine piperazine offers a new perspective for therapeutic intervention thereby inhibiting the spread of virus say researchers.

Currently there is no vaccine or anti-viral drug available in the market for the cure of chikungunya. The treatment has been focussed on relieving the symptoms associated with the virus infection.

The researchers spoke of the potential of piperazine as a pharmacotherapeutic agent and how binding these molecules to the hydrophobic pocket of capsid protein present in the Chikungunya virus offers a new perspective for therapeutic intervention thereby inhibiting the spread of the virus.

Piperazine is commonly used in deworming treatments against roundworm and pinworm.

"Developing a new antiviral drug molecule can take over a decade and that is the reason why we are looking at repositioning existing approved drugs and testing these to see if they can inhibit or kill pathogenic viruses " said Shailly Tomar from the Department of Biotechnology at IIT-Roorkee.

Research has shown that piperazine which is available in the market is successful in curbing the spread and replication of the chikungunya virus in a lab setting.

"We are currently testing the molecule on animals and hope to take this to clinical trials soon " said Tomar.

Chikungunya is a viral disease transmitted to humans by infected mosquitoes. It causes fever and severe joint pain. Other symptoms include muscle pain headache nausea fatigue and rash.

The researchers said they found that piperazine would bind itself well with the hydrophobic pocket on the alphavirus capsid protein.

"This pocket is key to the replication of the virus and its spread inside a host. This inhibition of this pocket prevents budding and spread of the virus and can help in treating the virus effectively using existing drugs " said they said.

Delhi saw the worst outbreak of chikungunya in 2016 with a total of 7 760 cases being reported from across the national capital. In 2017 Delhi has so far seen nearly 500 cases of Chikungunya.

--IANS
rup/nir/dg